JP2018527360A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527360A5
JP2018527360A5 JP2018512334A JP2018512334A JP2018527360A5 JP 2018527360 A5 JP2018527360 A5 JP 2018527360A5 JP 2018512334 A JP2018512334 A JP 2018512334A JP 2018512334 A JP2018512334 A JP 2018512334A JP 2018527360 A5 JP2018527360 A5 JP 2018527360A5
Authority
JP
Japan
Prior art keywords
moiety
compound according
protein
compound
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018512334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527360A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/052829 external-priority patent/WO2017053391A1/en
Publication of JP2018527360A publication Critical patent/JP2018527360A/ja
Publication of JP2018527360A5 publication Critical patent/JP2018527360A5/ja
Pending legal-status Critical Current

Links

JP2018512334A 2015-09-22 2016-09-21 修飾された細胞毒とその治療的使用 Pending JP2018527360A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222059P 2015-09-22 2015-09-22
US62/222,059 2015-09-22
PCT/US2016/052829 WO2017053391A1 (en) 2015-09-22 2016-09-21 Modified cytotoxins and their therapeutic use

Publications (2)

Publication Number Publication Date
JP2018527360A JP2018527360A (ja) 2018-09-20
JP2018527360A5 true JP2018527360A5 (enExample) 2019-10-31

Family

ID=58276138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018512334A Pending JP2018527360A (ja) 2015-09-22 2016-09-21 修飾された細胞毒とその治療的使用

Country Status (14)

Country Link
US (3) US10023581B2 (enExample)
EP (1) EP3353159A4 (enExample)
JP (1) JP2018527360A (enExample)
KR (1) KR20180045001A (enExample)
CN (1) CN108368075A (enExample)
AU (1) AU2016326392B2 (enExample)
CA (1) CA2998528A1 (enExample)
HK (1) HK1254461A1 (enExample)
IL (1) IL257932A (enExample)
MX (1) MX380314B (enExample)
MY (1) MY193776A (enExample)
RU (1) RU2721949C2 (enExample)
WO (1) WO2017053391A1 (enExample)
ZA (1) ZA201801482B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998528A1 (en) * 2015-09-22 2017-03-30 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
KR20190123351A (ko) * 2017-03-22 2019-10-31 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 개질된 올리고뉴클레오티드 및 이의 치료 용도
WO2021007322A1 (en) * 2019-07-09 2021-01-14 Northwestern University Methods of using modified cytotoxins to treat cancer
IT202100025172A1 (it) * 2021-09-30 2023-03-30 Indena Spa Processo per la preparazione di derivati tassanici
KR20250057244A (ko) 2023-10-20 2025-04-29 (주)블루엔씨 고정밀 3d 프린팅 기반 금형 제작 방법 및 장치

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411984A (en) 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
GB2278843A (en) * 1993-06-07 1994-12-14 British Tech Group Anti-cancer compounds
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
AU735205B2 (en) 1997-05-16 2001-07-05 Commonwealth Scientific And Industrial Research Organisation Vaccine and assay
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
AU2002953095A0 (en) * 2002-11-29 2002-12-19 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
NO319551B1 (no) 2003-07-04 2005-08-29 Thia Medica As Proteinmateriale fra enkeltceller
GB0321613D0 (en) 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
BR122019021416A2 (enExample) 2003-09-19 2019-12-21
RU2340616C2 (ru) * 2003-10-29 2008-12-10 Сонус Фармасьютикалз, Инк. Токоферол-модифицированные терапевтические лекарственные соединения
GB0412181D0 (en) * 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
EP1804838A2 (en) 2004-09-15 2007-07-11 Drug Discovery Laboratory AS Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
TW200731991A (en) * 2005-12-20 2007-09-01 Sonus Pharma Inc Lipophilic di(anticancer drug) compounds, compositions and related methods
DE112009000300T5 (de) 2008-02-08 2011-01-20 Aileron Therapeutics, Inc., Cambridge Therapeutische Peptidomimetische Makrocyclen
MX2010011165A (es) * 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
US20100240883A1 (en) 2009-03-18 2010-09-23 Nian Wu Lipid-drug conjugates for drug delivery
BRPI1015108A2 (pt) 2009-04-02 2016-04-26 Shire Llc pró-fármacos de aminoácidos e peptídios ligados a ácido dicarboxílico de opiáceos e seus usos
JP2013516471A (ja) * 2010-01-06 2013-05-13 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 薬物の脂肪酸誘導体および類似体
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
ES2582590T3 (es) 2010-02-16 2016-09-13 Novo Nordisk A/S Método de purificación
CA2800497C (en) 2010-05-10 2019-03-12 The Regents Of The University Of California Methods for preparing ratiometric combinatorial nanoparticules
EP2392324A1 (en) * 2010-06-01 2011-12-07 Societe De Coordination De Recherches Therapeutiques Rhenium complexes and their pharmaceutical use
CA2812951A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
WO2012048204A2 (en) 2010-10-08 2012-04-12 Virginia Commonwealth University Prodrugs utilizing a transporter directed uptake mechanism
CN103857440B (zh) 2011-06-22 2018-09-25 维奥姆生物科学有限公司 基于缀合物的抗真菌和抗细菌前药
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
KR101435261B1 (ko) 2012-07-23 2014-09-02 아주대학교산학협력단 항암제-링커-알부민 결합체, 이의 제조방법 및 상기 결합체를 포함하는 약물 전달용 조성물
WO2014078895A1 (en) * 2012-11-21 2014-05-30 The University Of Sydney Omega-3 analogues
WO2014121033A1 (en) * 2013-02-04 2014-08-07 Fl Therapeutics Llc Soluble complexes of drug analogs and albumin
US20160115192A1 (en) * 2013-06-10 2016-04-28 Cedars-Sinai Medical Center Antioxidant, anti-inflammatory and anticancer derivatives of triptolide and nanospheres thereof
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
CA2968145C (en) * 2014-11-17 2023-06-27 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
CN104478813A (zh) * 2014-12-20 2015-04-01 苏州博源医疗科技有限公司 5-氟尿嘧啶衍生物、5-氟尿嘧啶免疫原及其抗体与5-氟尿嘧啶检测试剂盒
CA2998528A1 (en) * 2015-09-22 2017-03-30 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US10286079B2 (en) * 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US20210137957A1 (en) * 2017-03-22 2021-05-13 The Regents Of The University Of California Modified anthracycline compounds and their therapeutic use
US20210137874A1 (en) * 2017-03-22 2021-05-13 The Regents Of The University Of California Modified platinum compounds and therapeutic uses thereof
US20200048198A1 (en) * 2017-03-22 2020-02-13 The Regents Of The University Of California Modified histone deacetylase inhibitors and uses thereof
KR20190135500A (ko) * 2017-04-27 2019-12-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 개질된 mri 조영제 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2018527360A5 (enExample)
CN104530417B (zh) 一种多官能化h型聚乙二醇衍生物及其制备方法
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
JP2016506916A5 (enExample)
RU2017112048A (ru) Синергистические комбинации ауристана
JP2017518302A5 (enExample)
JP2020097577A5 (enExample)
RU2021103727A (ru) Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией
JP2016539134A5 (enExample)
EP4410317A3 (en) Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP2019504100A5 (enExample)
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2017531619A5 (enExample)
CL2014000363A1 (es) Compuestos derivados de 1,2,5-oxadiazoles, inhibidores de indolamina 2,3-dioxigenasa; composicion farmaceutica; proceso para prepararlos; y su uso para el tratamiento de cancer, infeccion viral, depresion, desorden neurodegenerativo, trauma, cataratas, rechazo de transplante de un organo, enfermedades autoinmunes, entre otros.
JP2019521180A5 (enExample)
JP2017536344A5 (enExample)
JP2008200039A5 (enExample)
EP4275748A3 (en) Compositions and methods for treating cns disorders
JP2009504763A5 (enExample)
JP2010509366A5 (enExample)
JP2017526677A5 (enExample)
JP2017510610A5 (enExample)
JP2012506870A5 (enExample)
JP2016513696A5 (enExample)
CN114206338A (zh) 作为pd-l1抑制剂的二氢化茚类